Effects of Salbutamol in Athletes and Implications for Screening and Sports

University of British Columbia

Status: Not yet enrolling

Conditions: Healthy; Asthma; Effect of Drug

Treatments: Drug: Salbutamol; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT07037511

H24-01838

Details and patient eligibility

About

β2-Agonists, commonly used to treat asthma, have also been used by athletes to enhance performance, leading to their ban by the International Olympic Committee in 1972. Research has shown non-asthmatics receive no benefit from these drugs at therapeutic dosages; however, many elite athletes still use them, and asthmatic athletes often win more Olympic medals. In some non-asthmatics, β2-agonists may improve breathing limitations during high intensity exercise, which may improve performance. Therefore, we aim to examine if there is a select group of non-asthmatic individuals who experience breathing limitations that may receive benefit from β2-agonists.

Full description

Purpose:

The purpose of this study is to examine the effects of β2-agonists on exercise performance in non-asthmatic male and female endurance athletes.

Hypothesis:

Our primary hypothesis is that ß2-agonists will improve exercise duration to a greater degree in athletes who experience expiratory flow limitation (EFL) compared to those who do not experience EFL. Additionally, female athletes will, on average, experience greater benefits with ß2-agonists due to a greater prevalence of EFL than males.

Justification:

While β2-agonists have historically been used by athletes as an ergogenic aid, systematic reviews indicate their ineffectiveness in improving aerobic performance. Consequently, the World Anti-Doping Agency (WADA) revised regulations to allow controlled use of specific β2-agonists. Despite a lack of evidence supporting their ergogenic benefits, positive tests for supratherapeutic doses of salbutamol among elite athletes, such as cyclist Chris Froome and cross-country skier Martin Johnsrud Sundby, suggests a belief in their performance-enhancing capabilities. Additionally, there is a physiological rationale for some non-asthmatics to benefit from these drugs. For instance, therapeutic doses of β2-agonists can induce bronchodilation, resulting in a ~5% increase in forced expiratory volume in one second (FEV1) in non-asthmatics. While this level of bronchodilation does not meet the diagnostic threshold for asthma, it holds potential for enhancing ventilatory responses in certain athletes. For example, a subset of non-asthmatic athletes who develop EFL during exercise, characterized by the inability to increase expiratory flows despite increases in expiratory effort, may derive greater benefits if the bronchodilation is sufficient to attenuate EFL. Indeed, experimental reduction of EFL via breathing a helium-oxygen gas mixture improves ventilatory responses, gas exchange, and endurance performance in non-asthmatics. We speculate that non-asthmatics experiencing EFL during exercise are likely to benefit more from β2-agonists than those who do not develop EFL.

Statistical Analysis:

The effects of salbutamol vs. placebo on exercise duration in all participants will be compared using a paired t-test. In all cases, a P-value < 0.05 will be considered statistically significant. A total of 64 participants (32 males and 32 females) will be recruited to adequately assess the effects of salbutamol on exercise tolerance, dyspnea, and related physiological variables.

Enrollment: 64 estimated patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Aerobic capacity (V̇O2max) greater than 120% predicted
• Body mass index (BMI) > 18 and < 30 kg/m2
• Ability to read and understand English
• Currently training and/or competing in endurance sports (i.e. running or cycling)

Exclusion criteria

• Smoking history or currently smoking. Currently smoking is defined as regular use of cigarettes or cannabis at any point in the past year. History of smoking is defined as smoking more than 1 pack year for cigarettes or the equivalent in cannabis use measured as puffs per day / 200 (number of puffs in a pack of cigarettes).
• Use of cannabis within the past 30 days or has a smoking history of at least 1 pack year.
• Use of vaping devices or e-cigarettes in the past 30 days, or has used them more than 10 times in their lifetime.
• History or current symptoms of cardiopulmonary disease (excluding controlled asthma)
• Contraindications to exercise testing defined as anything that would prevent exercise under proper and safe conditions (e.g., a problem with the heart or lungs, muscle)
• Neuromuscular or musculoskeletal condition

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

64 participants in 2 patient groups, including a placebo group

Salbutamol inhaler

Active Comparator group

Description:

Participants will take four inhalations of salbutamol, with 60 seconds between each inhalation, totaling a therapeutic dose of 400µg of salbutamol prior to performing an incremental cardiopulmonary exercise test.

Treatment:

Drug: Salbutamol

Placebo inhaler

Placebo Comparator group

Description:

Participants will take four inhalations of placebo, with 60 seconds between each inhalation, prior to performing an incremental cardiopulmonary exercise test.

Treatment:

Drug: Placebo